The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens
Open accessThe DOI matches its Crossref record; 246 of the 246 references it cites were found in a registry or an index.
Abstract
Human fungal pathogens are attributable to a significant economic burden and mortality worldwide. Antifungal treatments, although limited in number, play a pivotal role in decreasing mortality and morbidities posed by invasive fungal infections (IFIs). However, the recent emergence of multidrug-resistant Candida auris and Candida glabrata and acquiring invasive infections due to azole-resistant C. parapsilosis, C. tropicalis, and Aspergillus spp. in azole-naïve patients pose a serious health threat considering the limited number of systemic antifungals available to treat IFIs. Although advancing for major fungal pathogens, the understanding of fungal attributes contributing to antifungal resistance is just emerging for several clinically important MDR fungal pathogens. Further complicating the matter are the distinct differences in antifungal resistance mechanisms among various fungal species in which one or more mechanisms may contribute to the resistance phenotype. In this review, we attempt to summarize the burden of antifungal resistance for selected non-albicansCandida and clinically important Aspergillus species together with their phylogenetic placement on the tree of life. Moreover, we highlight the different molecular mechanisms between antifungal tolerance and resistance, and comprehensively discuss the molecular mechanisms of antifungal resistance in a species level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Phylogenetic tree of Candida species studied in the current review, i.e., C. glabrata, C. parapsilosis, C. tropicalis, and C. auris (highlighted in blue). This tree was constructed using maximum likelihood of 11,570 core genes based on 1000 replicates. Asterikes does not serve any specific defnitions. This figure was adopted permission from Munoz et al., 2018 [20].](https://figures.cochat.ai/paper-figures/3e30acfc216a4d828861bcc55bf652a6/the-quiet-and-underappreciated-rise-of-drug-resistant-invasive-fungal-pathogens-figure-1.jpg)

![Figure 3 Pdr1p contains four domains. Numerous GOF mutations (black bars) can cause azole resistance. Adopted the permission from Ferrari et al., 2009 [98].](https://figures.cochat.ai/paper-figures/bd4edb3b814e44a689549f07abf351f4/the-quiet-and-underappreciated-rise-of-drug-resistant-invasive-fungal-pathogens-figure-3.jpg)

![Figure 5 Whole-genome sequence analysis of the US C. auris (up to 2018) isolates reveals the existence of four major clades. Isolates representing all identified clades have been recovered from the U.S. The Iranian clade is not shown in this figure. Adopted the permission from Chow et al., 2018 [201].](https://figures.cochat.ai/paper-figures/6559288ef9344e4d9a16d7f660126cfa/the-quiet-and-underappreciated-rise-of-drug-resistant-invasive-fungal-pathogens-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In the US, fluconazole resistance rates range between 4–10%; rates are much higher in other parts of the world including Japan, Western Europe, and Latin America.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [112]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“C. krusei is considered inherently resistant to fluconazole yet demonstrates variable susceptibility to both voriconazole and posaconazole.62,103,112”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fluconazole resistance has been reported in up to 75% of C. glabrata isolates in single center surveys, and resistance to the echinocandins ranges from 0% to 24% in larger studies.27,111–113”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resistance to the echinocandins has remained relatively infrequent (0–3%) despite a higher baseline susceptible MIC cutoff value compared to the other Candida spp. due to a naturally occurring polymorphism in FKS1.62,103,112,120”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resistance to the echinocandins has remained relatively infrequent (0–3%) despite a higher baseline susceptible MIC cutoff value compared to the other Candida spp. due to a naturally occurring polymorphism in FKS1.62,103,112,120”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [112]
Experimental — accuracy not yet measured
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662
Satoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1194 · Cited by 1,298
Phylogeny, identification and nomenclature of the genus Aspergillus
Samson, R. A., Visagie, C. M., Houbraken, J., Hong, S.-B., Hubka, V., Klaassen, C. H. W., Perrone, G., Seifert, K. A., Susca, A., Tanney, J. B., et al. (2014) · Studies in Mycology · doi:10.1016/j.simyco.2014.07.004 · Cited by 1,136
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Self-citationPfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · cited 1×
“At the institutional level, the prevalence of echinocandin resistance can vary significantly, reaching up to >13% at some centers [96].”
BackgroundSelf-citationHoward, S. J., Cerar, D., Anderson, M. J., Albarrag, A., Fisher, M. C., Pasqualotto, A. C., Laverdiere, M., Arendrup, M. C., Perlin, D. S., & Denning, D. W. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1507.090043 · Cited by 750
Self-citationHsp90 Potentiates the Rapid Evolution of New Traits: Drug Resistance in Diverse Fungi
Cowen, L. E., & Lindquist, S. (2005) · Science · doi:10.1126/science.1118370 · Cited by 698 · cited 2×
“the activation of efflux pumps (Figure 1) [29,31].”
BackgroundCandida Biofilms: Threats, Challenges, and Promising Strategies
Cavalheiro, M., & Teixeira, M. C. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00028 · Cited by 690
Mechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647 · cited 2×
“Fungal factors resulting in antifungal resistance involve various subcellular mechanisms, including alteration of the drug target, overexpression of efflux pumps and drug target, and gross chromosomal changes [10].”
BackgroundSelf-citationDrug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642 · cited 7×
“If incubated for 48 h, however, tolerant cells can grow at a drug level higher than MIC, which is due to slow growth of tolerant cells in presence of antifungal drugs relative to drug‐resistant isolates [11].”
BackgroundInfluentialChowdhary, A., Prakash, A., Sharma, C., Kordalewska, M., Kumar, A., Sarma, S., Tarai, B., Singh, A., Upadhyaya, G., Upadhyay, S., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx480 · Cited by 577
Self-citationChanges in the epidemiological landscape of invasive candidiasis
Lamoth, F., Lockhart, S. R., Berkow, E. L., & Calandra, T. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx444 · Cited by 547
Fungi in the healthy human gastrointestinal tract
Hallen-Adams, H. E., & Suhr, M. J. (2017) · Virulence · doi:10.1080/21505594.2016.1247140 · Cited by 526
On the emergence of Candida auris: climate change, azoles, swamps, and birds
Casadevall, A., Kontoyiannis, D. P., & Robert, V. (2019) · mBio · doi:10.1128/mbio.01397-19 · Cited by 515
Welsh, R. M., Bentz, M. L., Shams, A., Houston, H., Lyons, A., Rose, L. J., & Litvintseva, A. P. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.00921-17 · Cited by 499
Muñoz, J. F., Gade, L., Chow, N. A., Loparev, V. N., Juieng, P., Berkow, E. L., Farrer, R. A., Litvintseva, A. P., & Cuomo, C. A. (2018) · Nature Communications · doi:10.1038/s41467-018-07779-6 · Cited by 458 · cited 3×
“glabrata and belongs to the so-called Metschnikowia clade, which diverged earlier within the Saccharomycotina tree (Figure 1) [20].”
BackgroundMethodInfluentialIncidence, characteristics and outcome of ICU-acquired candidemia in India
Chakrabarti, A., Sood, P., Rudramurthy, S. M., Chen, S., Kaur, H., Capoor, M., Chhina, D., Rao, R., Eshwara, V. K., Xess, I., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-014-3603-2 · Cited by 454
Stimulation of Chitin Synthesis Rescues Candida albicans from Echinocandins
Walker, L. A., Munro, C. A., de Bruijn, I., Lenardon, M. D., McKinnon, A., & Gow, N. A. R. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000040 · Cited by 445 · cited 2×
“This is followed by the engagement of main signal transduction pathways involved in stress adaptation and cell wall integrity, including protein kinase C (PKC), high-osmolarity glycerol (HOG), and calcineurin pathways, activation of appropriate transcription factors, and, finally, expression of response element genes,…”
BackgroundCowen, L. E., Singh, S. D., Köhler, J. R., Collins, C., Zaas, A. K., Schell, W. A., Aziz, H., Mylonakis, E., Perfect, J. R., Whitesell, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813394106 · Cited by 413 · cited 3×
“However, in vivo and in vitro studies revealed that genetic impairment of HSP90 and/or calcineurin inhibitors potentiate the efficacy of fluconazole and caspofungin, rendering them fungicidal [43].”
BackgroundSanglard, D., Ischer, F., Parkinson, T., Falconer, D., & Bille, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2404-2412.2003 · Cited by 398
Multiple-Triazole–Resistant Aspergillosis
Verweij, P. E., Mellado, E., & Melchers, W. J. G. (2007) · New England Journal of Medicine · doi:10.1056/nejmc061720 · Cited by 380
Epidemiology of candidemia in Latin America: a laboratory-based survey
Nucci, M., Queiroz-Telles, F., Alvarado-Matute, T., Tiraboschi, I. N., Cortes, J., Zurita, J., Guzman-Blanco, M., Santolaya, M. E., Thompson, L., Sifuentes-Osornio, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059373 · Cited by 374
Echinocandin resistance in Candida.
Perlin, D. S. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ791 · Cited by 374 · cited 2×
“Elevated MIC values vary depending on the position and the nature of the amino acid substitution [52,53].”
BackgroundSelf-citationProspective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus
van der Linden, J. W. M., Arendrup, M. C., Warris, A., Lagrou, K., Pelloux, H., Hauser, P. M., Chryssanthou, E., Mellado, E., Kidd, S. E., Tortorano, A. M., et al. (2015) · Emerging Infectious Diseases · doi:10.3201/eid2106.140717 · Cited by 371
Self-citationHsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin
Singh, S. D., Robbins, N., Zaas, A. K., Schell, W. A., Perfect, J. R., & Cowen, L. E. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000532 · Cited by 362 · cited 3×
“glabrata isolates harboring mutati ns in FKS1 a d/or FKS2 ca be potenti t when used in combination with HSP90 inhibitors [36].”
BackgroundMethodPotential Fifth Clade of Candida auris, Iran, 2018
Chow, N. A., de Groot, T., Badali, H., Abastabar, M., Chiller, T. M., & Meis, J. F. (2019) · Emerging Infectious Diseases · doi:10.3201/eid2509.190686 · Cited by 356
A nuclear receptor-like pathway regulating multidrug resistance in fungi
Thakur, J. K., Arthanari, H., Yang, F., Pan, S.-J., Fan, X., Breger, J., Frueh, D. P., Gulshan, K., Li, D. K., Mylonakis, E., et al. (2008) · Nature · doi:10.1038/nature06836 · Cited by 343 · cited 2×
“Once an azole reaches a cell, it binds to the MHD and activates PDR1, followed by interaction of PDR1 and Gal11A on PDRE, RNA polymerase II recruitment, and the overexpression of downstream genes, such as efflux pumps [101].”
BackgroundLaFayette, S. L., Collins, C., Zaas, A. K., Schell, W. A., Betancourt-Quiroz, M., Gunatilaka, A. A. L., Perfect, J. R., & Cowen, L. E. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001069 · Cited by 329 · cited 2×
“the activation of efflux pumps (Figure 1) [29,31].”
BackgroundCandida parapsilosis: from genes to the bedside
Tóth, R., Nosek, J., Mora-Montes, H. M., Gabaldon, T., Bliss, J. M., Nosanchuk, J. D., Turner, S. A., Butler, G., Vágvölgyi, C., & Gácser, A. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00111-18 · Cited by 327
Zhai, B., Ola, M., Rolling, T., Tosini, N. L., Joshowitz, S., Littmann, E. R., Amoretti, L. A., Fontana, E., Wright, R. J., Miranda, E., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0709-7 · Cited by 327
Garcia-Effron, G., Katiyar, S. K., Park, S., Edlind, T. D., & Perlin, D. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00262-08 · Cited by 323
Self-citationSelmecki, A. M., Dulmage, K., Cowen, L. E., Anderson, J. B., & Berman, J. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000705 · Cited by 319 · cited 2×
“Some gross genomic re-arrangements, such as aneuploidy, occur at higher rates than a specific point mutation, particularly under stress conditions, and they seem to be well tolerated by the yeast cell [58,59].”
BackgroundFraczek, M. G., Bromley, M., Buied, A., Moore, C. B., Rajendran, R., Rautemaa, R., Ramage, G., Denning, D. W., & Bowyer, P. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt075 · Cited by 315
Denning, D. W., Park, S., Lass-Florl, C., Fraczek, M. G., Kirwan, M., Gore, R., Smith, J., Bueid, A., Moore, C. B., Bowyer, P., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir179 · Cited by 313
Self-citationAntifungal Agents in Agriculture: Friends and Foes of Public Health
Brauer, V. S., Rezende, C. P., Pessoni, A. M., De Paula, R. G., Rangappa, K. S., Nayaka, S. C., Gupta, V. K., & Almeida, F. (2019) · Biomolecules · doi:10.3390/biom9100521 · Cited by 305
Puig-Asensio, M., Padilla, B., Garnacho-Montero, J., Zaragoza, O., Aguado, J. M., Zaragoza, R., Montejo, M., Muñoz, P., Ruiz-Camps, I., Cuenca-Estrella, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12380 · Cited by 299
Echinocandin resistance: an emerging clinical problem?
Arendrup, M. C., & Perlin, D. S. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000111 · Cited by 299 · cited 1×
“Elevated MIC values vary depending on the position and the nature of the amino acid substitution [52,53].”
BackgroundSelf-citationLockhart, S. R., Iqbal, N., Cleveland, A. A., Farley, M. M., Harrison, L. H., Bolden, C. B., Baughman, W., Stein, B., Hollick, R., Park, B. J., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01283-12 · Cited by 299
Multidrug-Resistant Candida haemulonii and C. auris , Tel Aviv, Israel
Ben-Ami, R., Berman, J., Novikov, A., Bash, E., Shachor-Meyouhas, Y., Zakin, S., Maor, Y., Tarabia, J., Schechner, V., Adler, A., et al. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2302.161486 · Cited by 297
Ferrari, S., Ischer, F., Calabrese, D., Posteraro, B., Sanguinetti, M., Fadda, G., Rohde, B., Bauser, C., Bader, O., & Sanglard, D. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000268 · Cited by 295 · cited 1×
“Pdr1p contains four do ains. u erous F utations (black bars) can cause azole resistance. o te the er ission fro Ferrari et al., 2009 [98].”
BackgroundAn Update on Candida tropicalis Based on Basic and Clinical Approaches
Zuza-Alves, D. L., Silva-Rocha, W. P., & Chaves, G. M. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01927 · Cited by 295
Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms
Robbins, N., Uppuluri, P., Nett, J., Rajendran, R., Ramage, G., Lopez-Ribot, J. L., Andes, D., & Cowen, L. E. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002257 · Cited by 291
Chow, N. A., Gade, L., Tsay, S. V., Forsberg, K., Greenko, J. A., Southwick, K. L., Barrett, P. M., Kerins, J. L., Lockhart, S. R., Chiller, T. M., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30597-8 · Cited by 289 · cited 1×
“Adopted the permission from Chow et al., 2018 [201].”
MethodDiaz-Guerra, T. M., Mellado, E., Cuenca-Estrella, M., & Rodriguez-Tudela, J. L. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.1120-1124.2003 · Cited by 281
Aspergillus Section Fumigati : Antifungal Susceptibility Patterns and Sequence-Based Identification
Alcazar-Fuoli, L., Mellado, E., Alastruey-Izquierdo, A., Cuenca-Estrella, M., & Rodriguez-Tudela, J. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00942-07 · Cited by 258
Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris
Kordalewska, M., Lee, A., Park, S., Berrio, I., Chowdhary, A., Zhao, Y., & Perlin, D. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00238-18 · Cited by 247
Self-citationGenomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris
Rhodes, J., Abdolrasouli, A., Farrer, R. A., Cuomo, C. A., Aanensen, D. M., Armstrong-James, D., Fisher, M. C., & Schelenz, S. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-018-0045-x · Cited by 246
Pham, C. D., Iqbal, N., Bolden, C. B., Kuykendall, R. J., Harrison, L. H., Farley, M. M., Schaffner, W., Beldavs, Z. G., Chiller, T. M., Park, B. J., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03255-14 · Cited by 231
Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens
Ksiezopolska, E., & Gabaldón, T. (2018) · Genes · doi:10.3390/genes9090461 · Cited by 230
Self-citationCosta-de-Oliveira, S., & Rodrigues, A. G. (2020) · Microorganisms · doi:10.3390/microorganisms8020154 · Cited by 229
Structural mechanism of ergosterol regulation by fungal sterol transcription factor Upc2
Yang, H., Tong, J., Lee, C. W., Ha, S., Eom, S. H., & Im, Y. J. (2015) · Nature Communications · doi:10.1038/ncomms7129 · Cited by 223 · cited 3×
“Fluconazole resistance is mediated by both Upc2p and Pdr1p in C. glabrata.”
BackgroundNational Surveillance of Fungemia in Denmark (2004 to 2009)
Arendrup, M. C., Bruun, B., Christensen, J. J., Fuursted, K., Johansen, H. K., Kjældgaard, P., Knudsen, J. D., Kristensen, L., Møller, J., Nielsen, L., et al. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.01811-10 · Cited by 223
Escandón, P., Chow, N. A., Caceres, D. H., Gade, L., Berkow, E. L., Armstrong, P., Rivera, S., Misas, E., Duarte, C., Moulton-Meissner, H., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy411 · Cited by 222
Yeast ATP-Binding Cassette Transporters Conferring Multidrug Resistance
Prasad, R., & Goffeau, A. (2012) · Annual Review of Microbiology · doi:10.1146/annurev-micro-092611-150111 · Cited by 221
Kean, R., Delaney, C., Sherry, L., Borman, A., Johnson, E. M., Richardson, M. D., Rautemaa-Richardson, R., Williams, C., & Ramage, G. (2018) · mSphere · doi:10.1128/msphere.00334-18 · Cited by 220
Camps, S. M. T., Dutilh, B. E., Arendrup, M. C., Rijs, A. J. M. M., Snelders, E., Huynen, M. A., Verweij, P. E., & Melchers, W. J. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050034 · Cited by 212
Update on Candida krusei , a potential multidrug-resistant pathogen
Jamiu, A. T., Albertyn, J., Sebolai, O. M., & Pohl, C. H. (2020) · Medical Mycology · doi:10.1093/mmy/myaa031 · Cited by 211
Sagatova, A. A., Keniya, M. V., Wilson, R. K., Monk, B. C., & Tyndall, J. D. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00925-15 · Cited by 210
Mellado, E., Garcia-Effron, G., Alcazar-Fuoli, L., Cuenca-Estrella, M., & Rodriguez-Tudela, J. L. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.7.2747-2750.2004 · Cited by 210
Snelders, E., Karawajczyk, A., Schaftenaar, G., Verweij, P. E., & Melchers, W. J. G. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01599-09 · Cited by 206
Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management
Lestrade, P. P. A., Meis, J. F., Melchers, W. J. G., & Verweij, P. E. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.11.027 · Cited by 202
Mutations in TAC1B : a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris
Rybak, J. M., Muñoz, J. F., Barker, K. S., Parker, J. E., Esquivel, B. D., Berkow, E. L., Lockhart, S. R., Gade, L., Palmer, G. E., White, T. C., et al. (2020) · mBio · doi:10.1128/mbio.00365-20 · Cited by 202
Breakthrough invasive candidiasis in patients on micafungin.
Pfeiffer, C. D., Garcia-Effron, G., Zaas, A. K., Perfect, J. R., Perlin, D. S., & Alexander, B. D. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02390-09 · Cited by 196
Self-citationFungal Resistance to Echinocandins and the MDR Phenomenon in Candida glabrata
Healey, K. R., & Perlin, D. S. (2018) · Journal of Fungi · doi:10.3390/jof4030105 · Cited by 194
Self-citationFungal resistance to echinocandins and the MDR phenomenon in Candida glabrata
Healey, K., & Perlin, D. S. (2018) · doi:10.20944/preprints201808.0306.v1 · Cited by 194
Self-citationAspergillus fumigatus-Related Species in Clinical Practice
Lamoth, F. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00683 · Cited by 184
FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Beyda, N. D., John, J., Kilic, A., Alam, M. J., Lasco, T. M., & Garey, K. W. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu407 · Cited by 174
Triazole Resistance in Aspergillus Species: An Emerging Problem
Garcia‐Rubio, R., Cuenca‐Estrella, M., & Mellado, E. (2017) · Drugs · doi:10.1007/s40265-017-0714-4 · Cited by 173
Self-citationShields, R. K., Nguyen, M. H., Press, E. G., Kwa, A. L., Cheng, S., Du, C., & Clancy, C. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00027-12 · Cited by 171
Park, H.-S., Lee, S. C., Cardenas, M. E., & Heitman, J. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.08.004 · Cited by 168 · cited 2×
“However, molecular chaperones, such as HSP90, counteract the stressor effects by stabilizing critical and essential downstream client proteins, such as Mkcp and calcineurin, leading to stressor withstanding and tolerance [29,30].”
BackgroundChanging epidemiology of candidaemia in Australia
Chapman, B., Slavin, M., Marriott, D., Halliday, C., Kidd, S., Arthur, I., Bak, N., Heath, C. H., Kennedy, K., Morrissey, C. O., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw422 · Cited by 163
Ben-Ami, R., Garcia-Effron, G., Lewis, R. E., Gamarra, S., Leventakos, K., Perlin, D. S., & Kontoyiannis, D. P. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir351 · Cited by 162
Self-citationOn the Origins of a Species: What Might Explain the Rise of Candida auris?
Jackson, B. R., Chow, N., Forsberg, K., Litvintseva, A. P., Lockhart, S. R., Welsh, R., Vallabhaneni, S., & Chiller, T. (2019) · Journal of Fungi · doi:10.3390/jof5030058 · Cited by 162
Thompson, G. R., Wiederhold, N. P., Vallor, A. C., Villareal, N. C., Lewis, J. S., & Patterson, T. F. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00473-08 · Cited by 160
Geddes‐McAlister, J., & Shapiro, R. S. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13739 · Cited by 159
Portrait of Candida Species Biofilm Regulatory Network Genes
Araújo, D., Henriques, M., & Silva, S. M. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.09.004 · Cited by 154
Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China
Jiang, C., Dong, D., Yu, B., Cai, G., Wang, X., Ji, Y., & Peng, Y. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks481 · Cited by 153
Changing epidemiology of candidaemia in Australia
Chapman, B., Slavin, M., Marriott, D., Halliday, C., Kidd, S., Arthur, I., Bak, N., Heath, C. H., Kennedy, K., Morrissey, C. O., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx047 · Cited by 149
Govender, N. P., Patel, J., Magobo, R. E., Naicker, S., Wadula, J., Whitelaw, A., Coovadia, Y., Kularatne, R., Govind, C., Lockhart, S. R., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw091 · Cited by 147
Inhibiting fungal multidrug resistance by disrupting an activator–Mediator interaction
Nishikawa, J. L., Boeszoermenyi, A., Vale-Silva, L. A., Torelli, R., Posteraro, B., Sohn, Y.-J., Ji, F., Gelev, V., Sanglard, D., Sanguinetti, M., et al. (2016) · Nature · doi:10.1038/nature16963 · Cited by 146 · cited 1×
“glabrata in a mouse model of urinary tract infection when used alone [104].”
BackgroundRisk Factors for Candida tropicalis Fungemia in Patients with Cancer
Kontoyiannis, D. P., Vaziri, I., Hanna, H. A., Boktour, M., Thornby, J., Hachem, R., Bodey, G. P., & Raad, I. I. (2001) · Clinical Infectious Diseases · doi:10.1086/323812 · Cited by 143
Mechanisms of Azole Resistance in a Clinical Isolate of Candida tropicalis
Vandeputte, P., Larcher, G., Bergès, T., Renier, G., Chabasse, D., & Bouchara, J.-P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4608-4615.2005 · Cited by 141
Abrogation of Triazole Resistance upon Deletion of CDR1 in a Clinical Isolate of Candida auris
Rybak, J. M., Doorley, L. A., Nishimoto, A. T., Barker, K. S., Palmer, G. E., & Rogers, P. D. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00057-19 · Cited by 141
Antifungal susceptibility of invasive Candida bloodstream isolates from the Asia-Pacific region
Tan, T. Y., Hsu, L. Y., Alejandria, M. M., Chaiwarith, R., Chinniah, T., Chayakulkeeree, M., Choudhury, S., Chen, Y. H., Shin, J. H., Kiratisin, P., et al. (2016) · Medical Mycology · doi:10.1093/mmy/myv114 · Cited by 139
New species in Aspergillus section Terrei
Samson, R. A., Peterson, S. W., Frisvad, J. C., & Varga, J. (2011) · Studies in Mycology · doi:10.3114/sim.2011.69.04 · Cited by 137
Epidemiologic Shift in Candidemia Driven by Candida auris, South Africa, 2016–20171
van Schalkwyk, E., Mpembe, R. S., Thomas, J., Shuping, L., Ismail, H., Lowman, W., Karstaedt, A. S., Chibabhai, V., Wadula, J., Avenant, T., et al. (2019) · Emerging Infectious Diseases · doi:10.3201/eid2509.190040 · Cited by 137
Zimbeck, A. J., Iqbal, N., Ahlquist, A. M., Farley, M. M., Harrison, L. H., Chiller, T., & Lockhart, S. R. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00836-10 · Cited by 136
Kim, S. H., Iyer, K. R., Pardeshi, L., Muñoz, J. F., Robbins, N., Cuomo, C. A., Wong, K. H., & Cowen, L. E. (2019) · mBio · doi:10.1128/mbio.02529-18 · Cited by 136
Kwon, Y. J., Shin, J. H., Byun, S. A., Choi, M. J., Won, E. J., Lee, D., Lee, S. Y., Chun, S., Lee, J. H., Choi, H. J., et al. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.01624-18 · Cited by 135
Desnos-Ollivier, M., Bretagne, S., Raoux, D., Hoinard, D., Dromer, F., & Dannaoui, E. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00088-08 · Cited by 132
Recent experience with fungaemia: change in species distribution and azole resistance
Chakrabarti, A., Chatterjee, S. S., Rao, K. L. N., Zameer, M. M., Shivaprakash, M. R., Singhi, S., Singh, R., & Varma, S. C. (2009) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540902777105 · Cited by 132
Forastiero, A., Mesa-Arango, A. C., Alastruey-Izquierdo, A., Alcazar-Fuoli, L., Bernal-Martinez, L., Pelaez, T., Lopez, J. F., Grimalt, J. O., Gomez-Lopez, A., Cuesta, I., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00477-13 · Cited by 131
Recent trends in molecular diagnostics of yeast infections: from PCR to NGS
Consortium OPATHY, Arastehfar, A., Boekhout, T., Butler, G., De Cesare, G. B., Dolk, E., Gabaldón, T., Hafez, A., Hube, B., Hagen, F., et al. (2019) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuz015 · Cited by 131
Self-citationCandida spp. with Acquired Echinocandin Resistance, France, 2004–20101
Dannaoui, E., Desnos-Ollivier, M., Garcia-Hermoso, D., Grenouillet, F., Cassaing, S., Baixench, M.-T., Bretagne, S., Dromer, F., Lortholary, O., & the French Mycoses Study Group (2012) · Emerging infectious diseases · doi:10.3201/eid1801.110556 · Cited by 130
Rybak, J. M., Ge, W., Wiederhold, N. P., Parker, J. E., Kelly, S. L., Rogers, P. D., & Fortwendel, J. R. (2019) · mBio · doi:10.1128/mbio.00437-19 · Cited by 130
Garcia-Effron, G., Kontoyiannis, D. P., Lewis, R. E., & Perlin, D. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00802-08 · Cited by 129
Self-citationCandida glabrata Biofilms: How Far Have We Come?
Rodrigues, C., Rodrigues, M., Silva, S., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010011 · Cited by 129
Zhang, J., Snelders, E., Zwaan, B. J., Schoustra, S. E., Meis, J. F., van Dijk, K., Hagen, F., van der Beek, M. T., Kampinga, G. A., Zoll, J., et al. (2017) · mBio · doi:10.1128/mbio.00791-17 · Cited by 129
Bader, O., Weig, M., Reichard, U., Lugert, R., Kuhns, M., Christner, M., Held, J., Peter, S., Schumacher, U., Buchheidt, D., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00167-13 · Cited by 127
Astvad, K. M. T., Johansen, H. K., Røder, B. L., Rosenvinge, F. S., Knudsen, J. D., Lemming, L., Schønheyder, H. C., Hare, R. K., Kristensen, L., Nielsen, L., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01564-17 · Cited by 125
Thomaz, D. Y., de Almeida, J. N., Lima, G. M. E., Nunes, M. D. O., Camargo, C. H., Grenfell, R. D. C., Benard, G., & Del Negro, G. M. B. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02997 · Cited by 124
Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus
Whitesell, L., Robbins, N., Huang, D. S., McLellan, C. A., Shekhar-Guturja, T., LeBlanc, E. V., Nation, C. S., Hui, R., Hutchinson, A., Collins, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08248-w · Cited by 124
Fernández-Ruiz, M., Aguado, J. M., Almirante, B., Lora-Pablos, D., Padilla, B., Puig-Asensio, M., Montejo, M., García-Rodríguez, J., Pemán, J., Ruiz Pérez de Pipaón, M., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu158 · Cited by 122
Hodiamont, C. J., Dolman, K. M., Ten berge, I. J. M., Melchers, W. J. G., Verweij, P. E., & Pajkrt, D. (2009) · Medical Mycology · doi:10.1080/13693780802545600 · Cited by 122
Souza, A. C. R., Fuchs, B. B., Pinhati, H. M. S., Siqueira, R. A., Hagen, F., Meis, J. F., Mylonakis, E., & Colombo, A. L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01177-15 · Cited by 121
Cleary, J. D., Garcia-Effron, G., Chapman, S. W., & Perlin, D. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01568-07 · Cited by 118
Carreté, L., Ksiezopolska, E., Pegueroles, C., Gómez-Molero, E., Saus, E., Iraola-Guzmán, S., Loska, D., Bader, O., Fairhead, C., & Gabaldón, T. (2018) · Current Biology · doi:10.1016/j.cub.2017.11.027 · Cited by 118 · cited 1×
“Further, recent whole-genome sequencing analysis failed to identify consistent links between aneuploidy involving genes associated with drug resistance and increased-resistance profiles [62,63].”
BackgroundSelf-citationMolecular basis of antifungal drug resistance in yeasts
Morio, F., Jensen, R. H., Le Pape, P., & Arendrup, M. C. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.05.012 · Cited by 114
Hull, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Kelly, D. E., & Kelly, S. L. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06253-11 · Cited by 113
Grossman, N. T., Pham, C. D., Cleveland, A. A., & Lockhart, S. R. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04613-14 · Cited by 112
Yaguchi, T., Horie, Y., Tanaka, R., Matsuzawa, T., Ito, J., & Nishimura, K. (2007) · Nippon Ishinkin Gakkai Zasshi · doi:10.3314/jjmm.48.37 · Cited by 111
A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade
Tortorano, A. M., Prigitano, A., Lazzarini, C., Passera, M., Deiana, M. L., Cavinato, S., De Luca, C., Grancini, A., Lo Cascio, G., Ossi, C., et al. (2013) · Infection · doi:10.1007/s15010-013-0455-6 · Cited by 110
Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris
Berkow, E. L., & Lockhart, S. R. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.10.021 · Cited by 110
Arastehfar, A., Daneshnia, F., Hilmioğlu-Polat, S., Fang, W., Yaşar, M., Polat, F., Metin, D. Y., Rigole, P., Coenye, T., Ilkit, M., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01001-20 · Cited by 110
Self-citationDuesberg, P., Stindl, R., & Hehlmann, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201398998 · Cited by 106 · cited 1×
“Some gross genomic re-arrangements, such as aneuploidy, occur at higher rates than a specific point mutation, particularly under stress conditions, and they seem to be well tolerated by the yeast cell [58,59].”
BackgroundExtrolites of Aspergillus fumigatus and Other Pathogenic Species in Aspergillus Section Fumigati
Frisvad, J. C., & Larsen, T. O. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01485 · Cited by 106
MFS transportome of the human pathogenic yeast Candida albicans
Gaur, M., Puri, N., Manoharlal, R., Rai, V., Mukhopadhayay, G., Choudhury, D., & Prasad, R. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-579 · Cited by 105
Evolutionary genomics of yeast pathogens in the Saccharomycotina
Gabaldón, T., Naranjo-Ortíz, M. A., & Marcet-Houben, M. (2016) · FEMS Yeast Research · doi:10.1093/femsyr/fow064 · Cited by 105
Castanheira, M., Deshpande, L. M., Messer, S. A., Rhomberg, P. R., & Pfaller, M. A. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.09.003 · Cited by 105
Chapeland-Leclerc, F., Hennequin, C., Papon, N., Noël, T., Girard, A., Socié, G., Ribaud, P., & Lacroix, C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01138-09 · Cited by 104
Tashiro, M., Izumikawa, K., Hirano, K., Ide, S., Mihara, T., Hosogaya, N., Takazono, T., Morinaga, Y., Nakamura, S., Kurihara, S., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00514-12 · Cited by 102
Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species
Garcia-Effron, G., Chua, D. J., Tomada, J. R., DiPersio, J., Perlin, D. S., Ghannoum, M., & Bonilla, H. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00998-09 · Cited by 102
Self-citationZhao, Y., Prideaux, B., Nagasaki, Y., Lee, M. H., Chen, P.-Y., Blanc, L., Ho, H., Clancy, C. J., Nguyen, M. H., Dartois, V., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-17 · Cited by 102 · cited 1×
“For intraabdominal infections, the recommended standard of care drugs, the echinocandin micafungin, fails to achieve sufficient levels during therapy, while newer related drugs in clinical development show superior penetration properties [71].”
BackgroundSelf-citationTwenty-two years of candidaemia surveillance: results from a Norwegian national study
Hesstvedt, L., Gaustad, P., Andersen, C. T., Haarr, E., Hannula, R., Haukland, H. H., Hermansen, N. O., Larssen, K. W., Mylvaganam, H., Ranheim, T. E., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.06.008 · Cited by 101
van Ingen, J., van der Lee, H. A., Rijs, T. A. J., Zoll, J., Leenstra, T., Melchers, W. J. G., & Verweij, P. E. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku364 · Cited by 101
Lewis, J. S., Wiederhold, N. P., Wickes, B. L., Patterson, T. F., & Jorgensen, J. H. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01144-13 · Cited by 101
Arastehfar, A., Daneshnia, F., Hafez, A., Khodavaisy, S., Najafzadeh, M.-J., Charsizadeh, A., Zarrinfar, H., Salehi, M., Shahrabadi, Z. Z., Sasani, E., et al. (2020) · Medical Mycology · doi:10.1093/mmy/myz124 · Cited by 99
Self-citationBerkow, E. L., Manigaba, K., Parker, J. E., Barker, K. S., Kelly, S. L., & Rogers, P. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01358-15 · Cited by 95
Fan, X., Xiao, M., Zhang, D., Huang, J.-J., Wang, H., Hou, X., Zhang, L., Kong, F., Chen, S. C.-A., Tong, Z.-H., et al. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.11.007 · Cited by 94
Candida auris Dry Surface Biofilm (DSB) for Disinfectant Efficacy Testing
Ledwoch, K., & Maillard, J.-Y. (2018) · Materials · doi:10.3390/ma12010018 · Cited by 94
Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007
Poikonen, E., Lyytikäinen, O., Anttila, V.-J., Koivula, I., Lumio, J., Kotilainen, P., Syrjälä, H., & Ruutu, P. (2010) · BMC Infectious Diseases · doi:10.1186/1471-2334-10-312 · Cited by 93
Genetic Drivers of Multidrug Resistance in Candida glabrata
Healey, K. R., Jimenez Ortigosa, C., Shor, E., & Perlin, D. S. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01995 · Cited by 93 · cited 2×
“glabrata isolates to acquire in vitro resistance to antifungal drug(s) [60].”
BackgroundSelf-citationInvasive candidiasis in intensive care units in China: a multicentre prospective observational study
Guo, F., Yang, Y., Kang, Y., Zang, B., Cui, W., Qin, B., Qin, Y., Fang, Q., Qin, T., Jiang, D., et al. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt083 · Cited by 92
Zoran, T., Sartori, B., Sappl, L., Aigner, M., Sánchez, F., Rezusta, A., Chowdhary, A., Taj‐Aldeen, S. J., Arendrup, M. C., Oliveri, S. M., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00516 · Cited by 92
Self-citationMoran, C., Grussemeyer, C. A., Spalding, J. R., Benjamin, D. K., & Reed, S. D. (2010) · American Journal of Infection Control · doi:10.1016/j.ajic.2009.06.014 · Cited by 91
Hull, C. M., Bader, O., Parker, J. E., Weig, M., Gross, U., Warrilow, A. G. S., Kelly, D. E., & Kelly, S. L. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01145-12 · Cited by 90
Hybridization and emergence of virulence in opportunistic human yeast pathogens
Mixão, V., & Gabaldón, T. (2018) · Yeast · doi:10.1002/yea.3242 · Cited by 90
Choi, Y. J., Kim, Y.-J., Yong, D., Byun, J.-H., Kim, T. S., Chang, Y. S., Choi, M. J., Byeon, S. A., Won, E. J., Kim, S. H., et al. (2018) · Emerging Infectious Diseases · doi:10.3201/eid2409.180625 · Cited by 88
Singh, A. K., Singh, P. K., de Groot, T., Kumar, A., Mathur, P., Tarai, B., Sachdeva, N., Upadhyaya, G., Sarma, S., Meis, J. F. G. M., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz029 · Cited by 87
Mathur, P., Hasan, F., Singh, P. K., Malhotra, R., Walia, K., & Chowdhary, A. (2018) · Mycoses · doi:10.1111/myc.12790 · Cited by 86
Spettel, K., Barousch, W., Makristathis, A., Zeller, I., Nehr, M., Selitsch, B., Lackner, M., Rath, P.-M., Steinmann, J., & Willinger, B. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210397 · Cited by 86
Fan, X., Xiao, M., Liao, K., Kudinha, T., Wang, H., Zhang, L., Hou, X., Kong, F., & Xu, Y.-C. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00464 · Cited by 85
Lindberg, E., Hammarström, H., Ataollahy, N., & Kondori, N. (2019) · Scientific Reports · doi:10.1038/s41598-019-40280-8 · Cited by 84
Aspergillus terreus: Novel lessons learned on amphotericin B resistance
Posch, W., Blatzer, M., Wilflingseder, D., & Lass‐Flörl, C. (2018) · Medical Mycology · doi:10.1093/mmy/myx119 · Cited by 82
Self-citationAhmad, S., Joseph, L., Parker, J. E., Asadzadeh, M., Kelly, S. L., Meis, J. F., & Khan, Z. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01900-18 · Cited by 82
Fitness Trade-Offs Associated with the Evolution of Resistance to Antifungal Drug Combinations
Hill, J. A., O’Meara, T. R., & Cowen, L. E. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.009 · Cited by 80 · cited 7×
“Although resistance is a favorable trait for fungus in the presence of antifungals, considering the associated alteration of major cellular components, resistant isolates are typically less fit than their susceptible counterparts when examined in the absence of antifungal agent [45,65].”
BackgroundInfluentialAhmad, S., Khan, Z., Al‐Sweih, N., Alfouzan, W., & Joseph, L. (2020) · Mycoses · doi:10.1111/myc.13022 · Cited by 79
Arastehfar, A. A., Daneshnia, F., Najafzadeh, M. J., Hagen, F., Mahmoudi, S., Salehi, M., Zarrinfar, H., Namvar, Z., Zareshahrabadi, Z., Khodavaisy, S., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00206 · Cited by 76
Self-citationFischer, J., van Koningsbruggen-Rietschel, S., Rietschel, E., Vehreschild, M. J. G. T., Wisplinghoff, H., Kronke, M., & Hamprecht, A. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku009 · Cited by 75
Dellière, S., Healey, K., Gits-Muselli, M., Carrara, B., Barbaro, A., Guigue, N., Lecefel, C., Touratier, S., Desnos-Ollivier, M., Perlin, D. S., et al. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02038 · Cited by 75
Self-citationBranco, J., Ola, M., Silva, R. M., Fonseca, E. S. S., Gomes, N. C., Martins-Cruz, C., Silva, A. P., Silva-Dias, A., Pina‐Vaz, C., Erraught, C., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.02.002 · Cited by 75
Jiménez-Ortigosa, C., Moore, C., Denning, D. W., & Perlin, D. S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01277-17 · Cited by 72 · cited 1×
“fumigatus F675S 2 2 ND NF NA/WT NA/WT NA/WT F675S [135]”
Self-citationAzole and fungicide resistance in clinical and environmental Aspergillus fumigatus isolates
Meneau, I., & Sanglard, D. (2005) · Medical Mycology · doi:10.1080/13693780500090826 · Cited by 69
Choi, M. J., Won, E. J., Shin, J. H., Kim, S. H., Lee, W.-G., Kim, M.-N., Lee, K., Shin, M. G., Suh, S. P., Ryang, D. W., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02652-15 · Cited by 68
Tipping the balance both ways: drug resistance and virulence in Candida glabrata
Vale-Silva, L. A., & Sanglard, D. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov025 · Cited by 67
Vale-Silva, L., Ischer, F., Leibundgut-Landmann, S., & Sanglard, D. (2013) · Infection and Immunity · doi:10.1128/iai.00074-13 · Cited by 65 · cited 1×
“As discussed earlier, the GOF mutations in PDR1 play role in virulence and immune evasion [102].”
BackgroundKhan, Z., Ahmad, S., Al-Sweih, N., Mokaddas, E., Al-Banwan, K., Alfouzan, W., Al-Obaid, I., Al-Obaid, K., Asadzadeh, M., Jeragh, A., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0216250 · Cited by 65
Megri, Y., Arastehfar, A., Boekhout, T., Daneshnia, F., Hörtnagl, C., Sartori, B., Hafez, A., Pan, W., Lass-Flörl, C., & Hamrioui, B. (2020) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-020-00710-z · Cited by 65
Self-citationSatish, S., Jiménez-Ortigosa, C., Zhao, Y., Lee, M. H., Dolgov, E., Krüger, T., Park, S., Denning, D. W., Kniemeyer, O., Brakhage, A. A., et al. (2019) · mBio · doi:10.1128/mbio.00779-19 · Cited by 64
Self-citationIdentification of Mycoses in Developing Countries
Arastehfar, A., Wickes, B. L., Ilkit, M., Pincus, D. H., Daneshnia, F., Pan, W., Fang, W., & Boekhout, T. (2019) · Journal of Fungi · doi:10.3390/jof5040090 · Cited by 63
Self-citationZhang, L., Xiao, M., Watts, M. R., Wang, H., Fan, X., Kong, F., & Xu, Y.-C. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1086-6 · Cited by 62
A prospective international Aspergillus terreus survey: an EFISG, ISHAM and ECMM joint study
Risslegger, B., Zoran, T., Lackner, M., Aigner, M., Sánchez, F., Rezusta, A., Chowdhary, A., Taj‐Aldeen, S. J., Arendrup, M. C., Oliveri, S. M., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.04.012 · Cited by 61
Self-citationAlastruey‐Izquierdo, A., Alcázar‐Fuoli, L., Rivero-Menéndez, O., Ayats, J., Castro, C., García‐Rodríguez, J., Goterris, L., Ibáñez-Martínez, E., Linares-Sicilia, M. J., Martín-Gómez, M. T., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00358-18 · Cited by 61
Chou, H.-H., Lo, H., Chen, K.-W., Liao, M.-H., & Li, S. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.03.014 · Cited by 59
Vu, B. G., Thomas, G. H., & Moye-Rowley, W. S. (2019) · mBio · doi:10.1128/mbio.00934-19 · Cited by 59
Clade II Candida auris possess genomic structural variations related to an ancestral strain
Sekizuka, T., Iguchi, S., Umeyama, T., Inamine, Y., Makimura, K., Kuroda, M., Miyazaki, Y., & Kikuchi, K. (2019) · PLOS ONE · doi:10.1371/journal.pone.0223433 · Cited by 59
Piper, P. W., Panaretou, B., Millson, S. H., Trumana, A., Mollapour, M., Pearl, L. H., & Prodromou, C. (2003) · Gene · doi:10.1016/s0378-1119(02)01102-2 · Cited by 58
Carreté, L., Ksiezopolska, E., Gómez-Molero, E., Angoulvant, A., Bader, O., Fairhead, C., & Gabaldón, T. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00112 · Cited by 58 · cited 1×
“Further, recent whole-genome sequencing analysis failed to identify consistent links between aneuploidy involving genes associated with drug resistance and increased-resistance profiles [62,63].”
BackgroundSelf-citationMoreno-Velásquez, S. D., Seidel, C., Juvvadi, P. R., Steinbach, W. J., & Read, N. D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00710-17 · Cited by 57 · cited 2×
“The inhibition of growth at MIC involves a relocalization of β-1,3-d-glucan synthase complex (Fks1p and Rho) from cell wall to vacuole, while continuous exposure to high MIC after 48 h results in returning of this complex to cell wall, which results in normal growth [38].”
BackgroundHealey, K. R., Nagasaki, Y., Zimmerman, M., Kordalewska, M., Park, S., Zhao, Y., & Perlin, D. S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01412-17 · Cited by 57
Self-citationStavrou, A. A., Lackner, M., Lass‐Flörl, C., & Boekhout, T. (2019) · FEMS Yeast Research · doi:10.1093/femsyr/foz037 · Cited by 57
Self-citationChanging epidemiology of candidemia in a medical center in middle Taiwan
Hii, I.-M., Chang, H.-L., Lin, L.-C., Lee, Y.-L., Liu, Y.-M., Liu, C.-E., Chen, C.-H., Cheng, Y.-R., & Chang, C.-Y. (2015) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2013.08.017 · Cited by 56
Singh, A., Healey, K. R., Yadav, P., Upadhyaya, G., Sachdeva, N., Sarma, S., Kumar, A., Tarai, B., Perlin, D. S., & Chowdhary, A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00195-18 · Cited by 56
Self-citationJin, L., Cao, Z., Wang, Q., Wang, Y., Wang, X., Chen, H., & Wang, H. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3082-0 · Cited by 56
Hare, R. K., Gertsen, J. B., Astvad, K. M. T., Degn, K. B., Løkke, A., Stegger, M., Andersen, P. S., Kristensen, L., & Arendrup, M. C. (2019) · Emerging Infectious Diseases · doi:10.3201/eid2503.180297 · Cited by 54
Molecular mechanisms of azole resistance in Candida bloodstream isolates
Teo, J. Q.-M., Lee, S. J.-Y., Tan, A.-L., Lim, R. S.-M., Cai, Y., Lim, T.-P., & Kwa, A. L.-H. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-3672-5 · Cited by 54
Antifungal resistance in Aspergillus terreus: A current scenario
Vahedi‐Shahandashti, R., & Lass‐Flörl, C. (2019) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2019.103247 · Cited by 54
Self-citationAsadzadeh, M., Ahmad, S., Al‐Sweih, N., & Khan, Z. (2017) · Microbial Drug Resistance · doi:10.1089/mdr.2016.0336 · Cited by 53
UPC2A Is Required for High-Level Azole Antifungal Resistance in Candida glabrata
Whaley, S. G., Caudle, K. E., Vermitsky, J.-P., Chadwick, S. G., Toner, G., Barker, K. S., Gygax, S. E., & Rogers, P. D. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02217-13 · Cited by 52
Arastehfar, A., Daneshnia, F., Hilmioglu-Polat, S., Ilkit, M., Yasar, M., Polat, F., Metin, D. Y., Dokumcu, Ü. Z., Pan, W., Hagen, F., et al. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa419 · Cited by 52
Self-citationPelaez, T., Gijón, P., Bunsow, E., Bouza, E., Sánchez-Yebra, W., Valerio, M., Gama, B., Cuenca-Estrella, M., & Mellado, E. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00329-12 · Cited by 51
Chen, P.-Y., Chuang, Y.-C., Wu, U.-I., Sun, H.-Y., Wang, J.-T., Sheng, W.-H., Lo, H.-J., Wang, H.-Y., Chen, Y.-C., & Chang, S.-C. (2019) · Emerging Infectious Diseases · doi:10.3201/eid2509.190520 · Cited by 51
Branco, J., Silva, A. P., Silva, R. M., Silva-Dias, A., Pina-Vaz, C., Butler, G., Rodrigues, A. G., & Miranda, I. M. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00842-15 · Cited by 49
Marcos-Zambrano, L. J., Escribano, P., Sánchez, C., Muñoz, P., Bouza, E., & Guinea, J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02670-14 · Cited by 49
Klotz, U., Schmidt, D., Willinger, B., Steinmann, E., Buer, J., Rath, P., & Steinmann, J. (2016) · Mycoses · doi:10.1111/myc.12472 · Cited by 49
Perlin, D. S., & Wiederhold, N. P. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix121 · Cited by 49
Self-citationBiswas, C., Marcelino, V. R., Van Hal, S., Halliday, C., Martinez, E., Wang, Q., Kidd, S., Kennedy, K., Marriott, D., Morrissey, C. O., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02946 · Cited by 49
Howard, S. J., Livermore, J., Sharp, A., Goodwin, J., Gregson, L., Alastruey-Izquierdo, A., Perlin, D. S., Warn, P. A., & Hope, W. W. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00621-11 · Cited by 48
Self-citationChiotos, K., Vendetti, N., Zaoutis, T. E., Baddley, J., Ostrosky-Zeichner, L., Pappas, P., & Fisher, B. T. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw305 · Cited by 48
Jensen, R. H., Johansen, H. K., & Arendrup, M. C. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01193-12 · Cited by 47 · cited 1×
“glabrata, this yeast can develop antifungal resistance during the course of antifungal therapy [125,126,143].”
BackgroundRivero-Menéndez, O., Navarro-Rodríguez, P., Bernal‐Martínez, L., Martin-Cano, G., Lopez-Perez, L., Sánchez‐Romero, I., Pérez‐Ayala, A., Capilla, J., Zaragoza, Ó., & Alastruey‐Izquierdo, A. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01585 · Cited by 47
Ko, J., Jung, D. S., Lee, J. Y., Kim, H. A., Ryu, S. Y., Jung, S., Joo, E., Cheon, S., Ys, K., Kim, S., et al. (2019) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2019.05.017 · Cited by 46
Bromley, M., Johns, A., Davies, E., Fraczek, M., Mabey Gilsenan, J., Kurbatova, N., Keays, M., Kapushesky, M., Gut, M., Gut, I., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158724 · Cited by 45
Treatment of Infections Due to Aspergillus terreus Species Complex
Lass‐Flörl, C. (2018) · Journal of Fungi · doi:10.3390/jof4030083 · Cited by 45
Self-citationEchinocandin Resistance in Candida Species Isolates from Liver Transplant Recipients
Prigent, G., Aït-Ammar, N., Levesque, E., Fekkar, A., Costa, J.-M., El Anbassi, S., Foulet, F., Duvoux, C., Merle, J.-C., Dannaoui, E., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01229-16 · Cited by 44
Cited by
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
“In pathogenic yeasts, ABC and MFS transporters are mainly overexpressed by GOF mutations in TAC1 and MRR1, respectively [19, 30, 46].”
BackgroundSelf-citationDrug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium
Arastehfar, A., Gabaldón, T., Garcia-Rubio, R., Jenks, J. D., Hoenigl, M., Salzer, H. J. F., Ilkit, M., Lass-Flörl, C., & Perlin, D. S. (2020) · Antibiotics · doi:10.3390/antibiotics9120877 · Cited by 292
“Using this standard, echinocandin resistance among Candida species is ideally suited for resistance assessment, as is azole resistance among Aspergillus, as there is a strong correlation between clinical resistance, MIC and specific mutations in target genes [133].”
BackgroundInfluentialSelf-citationAn Overview of the Recent Advances in Antimicrobial Resistance
Oliveira, M., Antunes, W., Mota, S., Madureira-Carvalho, Á., Dinis-Oliveira, R. J., & Dias da Silva, D. (2024) · Microorganisms · doi:10.3390/microorganisms12091920 · Cited by 285
“Better knowledge of these resistance mechanisms would assist in developing alternative therapeutic strategies to combat refractory mycoses [80,81].”
Arastehfar, A., Carvalho, A., Nguyen, M. H., Hedayati, M. T., Netea, M. G., Perlin, D. S., & Hoenigl, M. (2020) · Journal of Fungi · doi:10.3390/jof6040211 · Cited by 272
Self-citationDaneshnia, F., de Almeida Júnior, J. N., Ilkit, M., Lombardi, L., Perry, A. M., Gao, M., Nobile, C. J., Egger, M., Perlin, D. S., Zhai, B., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00067-8 · Cited by 257
Self-citation
Metadata
- Authors
- Arastehfar, A., Lass-Flörl, C., Garcia-Rubio, R., Daneshnia, F., Ilkit, M., Boekhout, T., Gabaldon, T., & Perlin, D. S.
- Affiliations
- Hackensack Meridian Health (US)
- Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, 6020 Innsbruck, Austria
- Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA
- Westerdijk Fungal Biodiversity Institute (NL)
- Division of Mycology, University of Çukurova, 01330 Adana, Turkey
- Life Sciences Programme, Barcelona, Supercomputing Center (BSC-CNS), Jordi Girona, 08034 Barcelona, Spain
- Corresponding author
- Arastehfar, Amir
- Perlin, David S.
- ORCID
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2020-08-18
- Volume
- 6
- Issue
- 3
- Pages
- 138
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC7557958
- OpenAlex
- W3070435984
- Semantic Scholar
- ffe1b3b580b5ee9de9aca8e5de0b85b315b7691d
- Cited by
- 145
- References
- 246
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 36 · 2023: 28 · 2022: 22 · 2021: 25 · 2020: 7
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UPCommons institutional repository (Universitat Politècnica de Catalunya) (acceptedVersion, cc-by)
- UvA-DARE (University of Amsterdam) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- KNAW Research Portal (The Royal Netherlands Academy of Arts and Sciences) (submittedVersion, other-oa)
- KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (submittedVersion, other-oa)
- Funders
- Astellas Pharma
- National Institutes of Health (AI109025)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- antifungal resistance, invasive fungal infections, Candida auris, Candida glabrata, Candida parapsilosis, Candida tropicalis, Aspergillus, multidrug resistance, azole resistance, antifungal tolerance, molecular mechanisms of resistance, non-albicans Candida, phylogenetic placement
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.